Bli medlem
Bli medlem

Du är här

2021-08-11

Invitation to presentation of Xbrane Biopharma’s interim report January – June, 2021 on August 13, 2021.

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on August 13, 2021, at 10.00 a.m. CET. Xbrane will publish the company’s interim report for January – June, 2021, on Friday August 13, 2021, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report for January - June 2021, followed by a Q&A session. The presentation will be in English. To attend, please follow the link or dial-in at one of the numbers below:

Web link:
https://edge.media-server.com/mmc/p/e2styz5g

Confirmation Code: 1974425
Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): +44 (0) 800 279 66 19
Sweden (Local): +46 (0) 856 618 467
Sweden (TollFree): +46 (0) 20 012 51 60
US (Local): +1 646 741 31 67
US (TollFree): +1 877 870 91 35

Contacts


Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us


Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilars in its pipeline targeting € 7.9bn in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE.
For more information, visit www.xbrane.com.

Attachments


Invitation to presentation of Xbrane Biopharma’s interim report January – June, 2021 on August 13, 2021.

Författare MFN